Women with very advanced breast cancer may have a new treatment option. A combination of two drugs that more precisely target tumours significantly extended the lives of women who had stopped responding to other treatments, doctors reported.
"It's kind of like having a double brake on your tumour. If the first one fails, the second one does the job," said the Dr Kimberly Blackwell of Duke University. She led the study and has consulted for its sponsor, British-based GlaxoSmithKline PLC, which makes Tykerb, and for Genentech, which makes Herceptin.